Company intelligence / Profile preview

EnzymeRx, LLC

Paramus, New Jersey, United Statessec.gov ↗

Ownership: Private
Employees: ~6
Development stage: Phase 1

Overview

EnzymeRx has completed enrollment of its first clinical trial of pegsitacase (formerly Uricase PEG 20) and launched a second clinical study. The company is developing pegsitacase for refractory gout and hyperuricemia associated with tumor lysis syndrome. As of February 2010, they had completed a single-dose intravenous study and were conducting a phase 1b trial studying single and multiple intramuscular doses.

Therapeutic areas: Metabolic DisordersRheumatologyOncology
Modalities: Enzyme-based therapeuticsPegylated enzymes
Industry: Biotech

Drug pipeline

1 asset

pegsiticase

Phase 1

Indications: Refractory gout, Tumor lysis syndrome, Lesch-Nyhan syndrome

Beyond the preview

Go deeper on EnzymeRx, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnzymeRx, LLC.

Explore the full profile